A comparative analysis between low-dose-rate brachytherapy and external beam radiation therapy for low- and intermediate-risk prostate cancer in Asian men

References

• Dearnaley DP, Jovic G, Syndikus I, et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2014;15(4):464–473.
   PubMed Web of Science ®Google Scholar
• Heemsbergen WD, Al-Mamgani A, Slot A, et al. Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiother Oncol. 2014;110(1):104–109.
   PubMed Web of Science ®Google Scholar
• Beckendorf V, Guerif S, Le Prisé E, et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys. 2011;80(4):1056–1063.
   PubMed Web of Science ®Google Scholar
• Kishan AU, Dang A, Katz AJ, et al. Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer. JAMA Netw Open. 2019;2(2):e188006.
   PubMed Web of Science ®Google Scholar
• Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial [published correction appears in Lancet Oncol. 2016 Aug;17 (8): e321]. Lancet Oncol. 2016;17(8):1047–1060.
   PubMed Web of Science ®Google Scholar
• Sathya JR, Davis IR, Julian JA, et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol. 2005;23(6):1192–1199.
   PubMed Web of Science ®Google Scholar
• Hoskin PJ, Rojas AM, Bownes PJ, et al. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol. 2012;103(2):217–222.
   PubMed Web of Science ®Google Scholar
• Smith GD, Pickles T, Crook J, et al. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis. Int J Radiat Oncol Biol Phys. 2015;91(3):505–516.
   PubMed Web of Science ®Google Scholar
• Pickles T, Keyes M, Morris WJ. Brachytherapy or conformal external radiotherapy for prostate cancer: a single-institution matched-pair analysis. Int J Radiat Oncol Biol Phys. 2010;76(1):43–49.
   PubMed Web of Science ®Google Scholar
• Suvarna VR. Real world evidence (RWE) – are we (RWE) ready? Perspect Clin Res. 2018;9(2):61–63.
   PubMedGoogle Scholar
• Hamdy FC, Donovan JL, Lane JA, et al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375(15):1415–1424.
   PubMed Web of Science ®Google Scholar
• Goldner G, Pötter R, Battermann JJ, et al. Comparison of seed brachytherapy or external beam radiotherapy (70 Gy or 74 Gy) in 919 low-risk prostate cancer patients. Strahlenther Onkol. 2012;188(4):305–310.
   PubMed Web of Science ®Google Scholar
• Morris WJ, Tyldesley S, Rodda S, et al. Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2017;98(2):275–285.
   PubMed Web of Science ®Google Scholar
• Widmark A, Gunnlaugsson A, Beckman L, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019;394(10196):385–395.
   PubMed Web of Science ®Google Scholar
• Lehrer EJ, Kishan AU, Yu JB, et al. Ultrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: a systematic review and meta-analysis of phase III randomized trials [published online ahead of print, 2020 Apr 28]. Radiother Oncol. 2020;148:235–242.
   PubMed Web of Science ®Google Scholar
• Pinkawa M, Piroth MD, Fischedick K, et al. Self-assessed bowel toxicity after external beam radiotherapy for prostate cancer–predictive factors on irritative symptoms, incontinence and rectal bleeding. Radiat Oncol. 2009;4(1):36.
   PubMedGoogle Scholar
• Zumsteg ZS, Spratt DE, Pei I, et al. A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol. 2013;64(6):895–902.
   PubMed Web of Science ®Google Scholar